Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.

Tipranavir is a novel, non-peptidic protease inhibitor, which possesses broad antiviral activity against multiple protease inhibitor-resistant HIV-1. Resistance to this inhibitor however has not yet been well described. HIV was passaged for 9 months in culture in the presence of tipranavir to select HIV with a drug-resistant phenotype. Characterization of the selected variants revealed that the first mutations to be selected were L33F and I84V in the viral protease, mutations which together conferred less than two-fold resistance to tipranavir. At the end of the selection experiments, viruses harbouring 10 mutations in the protease (L10F, I13V, V32I, L33F, M36I, K45I, I54V, A71V, V82L, I84V) as well as a mutation in the CA/SP1 gag cleavage site were selected and showed 87-fold decreased susceptibility to tipranavir. In vitro, tipranavir-resistant viruses had a reduced replicative capacity which could not be improved by the introduction of the CA/SP1 cleavage site mutation. Tipranavir resistant viruses showed cross-resistance to other currently approved protease inhibitors with the exception of saquinavir. These results demonstrate that the tipranavir resistance phenotype is associated with complex genotypic changes in the protease. Resistance necessitates the sequential accumulation of multiple mutations.

[1]  C. Aiken,et al.  The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid , 2004, Retrovirology.

[2]  R. Myers,et al.  In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease , 1995, Journal of virology.

[3]  J. Martinez-Picado,et al.  Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 , 1999, Journal of Virology.

[4]  Brendan A. Larder,et al.  Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples , 2000, AIDS.

[5]  P. Harrigan,et al.  Human Immunodeficiency Virus Type 1 Protease Cleavage Site Mutations Associated with Protease Inhibitor Cross-Resistance Selected by Indinavir, Ritonavir, and/or Saquinavir , 2001, Journal of Virology.

[6]  B. Berkhout.  HIV-1 Evolution under Pressure of Protease Inhibitors: Climbing the Stairs of Viral Fitness , 1999, Journal of Biomedical Science.

[7]  C. Boucher,et al.  Implications of antiretroviral resistance on viral fitness , 2001, Current opinion in infectious diseases.

[8]  D. Lamarre,et al.  Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors , 1996, Journal of virology.

[9]  M. Moroni,et al.  Susceptibility to PNU-140690 (Tipranavir) of Human Immunodeficiency Virus Type 1 Isolates Derived from Patients with Multidrug Resistance to Other Protease Inhibitors , 2000, Antimicrobial Agents and Chemotherapy.

[10]  T. Perneger,et al.  Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. , 1999, AIDS.

[11]  M. Kazatchkine,et al.  The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients. , 2000, Antiviral research.

[12]  M. Kazatchkine,et al.  Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. , 1999, AIDS.

[13]  Esther Race,et al.  Cross-Resistance within the Protease Inhibitor Class , 2000, Antiviral therapy.

[14]  R. Myers,et al.  HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays. , 2000, AIDS research and human retroviruses.

[15]  E D Blair,et al.  Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors , 1995, Antimicrobial agents and chemotherapy.

[16]  A. Molla,et al.  Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir. , 2003, Antiviral research.

[17]  David E. Martin,et al.  PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Elston,et al.  Changes in Human Immunodeficiency Virus Type 1 Gag at Positions L449 and P453 Are Linked to I50V Protease Mutants In Vivo and Cause Reduction of Sensitivity to Amprenavir and Improved Viral Fitness In Vitro , 2002, Journal of Virology.

[19]  Wolfgang Resch,et al.  Selection of High-Level Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors , 2003, Antimicrobial Agents and Chemotherapy.

[20]  D. Ho,et al.  Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor , 1997, Antimicrobial agents and chemotherapy.

[21]  F. Mammano,et al.  Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypic Analysis of Protease andgag Coevolution in Protease Inhibitor-Treated Patients , 1998, Journal of Virology.

[22]  A. Telenti,et al.  Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. , 2000, AIDS research and human retroviruses.

[23]  Brendan A. Larder,et al.  Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples , 2000, AIDS.

[24]  V. Soriano,et al.  Resistance to HIV protease inhibitors: mechanisms and clinical consequences. , 2004, Current drug metabolism.

[25]  Timothy P. Spicer,et al.  In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632 , 2000, Antimicrobial Agents and Chemotherapy.

[26]  J. Falloon,et al.  Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites , 1997, Journal of virology.

[27]  A. van der Eb,et al.  A new technique for the assay of infectivity of human adenovirus 5 DNA. , 1973, Virology.

[28]  D. Ho,et al.  Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor , 1995, Journal of virology.

[29]  T. Merigan,et al.  Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. , 1999, AIDS.

[30]  F. Baldanti,et al.  Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART. , 2000, Antiviral research.

[31]  K. Hertogs,et al.  Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene. , 2001, AIDS research and human retroviruses.

[32]  J. Randolph,et al.  Peptidomimetic inhibitors of HIV protease. , 2004, Current topics in medicinal chemistry.

[33]  D. Ho,et al.  Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease , 1996, Antimicrobial agents and chemotherapy.

[34]  H. Gendelman,et al.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone , 1986, Journal of virology.

[35]  C. Boucher,et al.  Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. , 1999, AIDS.

[36]  D. Lamarre,et al.  Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors , 1997, Journal of virology.

[37]  C. Aiken,et al.  Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Replication by Specific Targeting of the Final Step of Virion Maturation , 2004, Journal of Virology.

[38]  T. Merigan,et al.  Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. , 1999, AIDS.

[39]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[40]  C. Boucher,et al.  In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. , 2000, AIDS.

[41]  I B Duncan,et al.  Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. , 1995, Virology.

[42]  Dale J. Kempf,et al.  In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to ABT-378, a Novel Protease Inhibitor , 1998, Journal of Virology.

[43]  J. Tolson,et al.  Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy. , 2001, AIDS research and human retroviruses.